|
Press Releases |
|
|
|
Wednesday, June 2, 2021 |
|
エーザイ、人事異動(2021年6月1日付)を発表 |
エーザイ株式会社は本日、人事異動(2021年6月1日付)を発表しました。 more info >> |
|
Wednesday, July 31, 2019 |
|
エーザイ、E2082の臨床第I相試験(治験)における死亡例の発生について |
当社が日本国内で実施していた健康成人を対象とした臨床第I相試験(治験)において、2019 年6 月に、1 名の被験者様が治験薬の投与を完了後にお亡くなりになりました。被験者様のご冥福をお祈り申し上げると共に、ご遺族様には謹んでお悔やみ申し上げます。 more info >> |
|
Tuesday, February 20, 2024 |
|
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives |
Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc. more info >> |
|
Friday, February 16, 2024 |
|
エーザイ、「メトジェクト(R)皮下注ペン」(一般名:メトトレキサート)が日本においてペン型自動注入器注射剤の承認を取得 |
more info >> |
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan |
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate). more info >> |
|
Thursday, February 1, 2024 |
|
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa |
Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa. more info >> |
|
Friday, January 26, 2024 |
|
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis |
Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan. more info >> |
|
Thursday, January 18, 2024 |
|
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan |
Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. more info >> |
|
Wednesday, January 17, 2024 |
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time |
Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
Tuesday, January 16, 2024 |
|
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 |
Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
国美零售瘦身聚焦主业
Mar 29, 2024 15:20 HKT/SGT
|
|
|
國美零售瘦身聚焦主業
Mar 29, 2024 15:15 HKT/SGT
|
|
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 15:07 HKT/SGT
|
|
|
国美金融科技公布2023年度业绩
Mar 29, 2024 14:53 HKT/SGT
|
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 15:51 JST
|
|
|
國美金融科技公佈2023年度業績
Mar 29, 2024 14:46 HKT/SGT
|
|
|
Gome Fin Tech Announced Annual Results of 2023
Mar 29, 2024 14:36 HKT/SGT
|
|
|
碧瑶绿色2023年度经调整纯利增加36.7%
Mar 29, 2024 14:26 HKT/SGT
|
|
|
碧瑤綠色2023年度經調整純利增加36.7%
Mar 29, 2024 14:21 HKT/SGT
|
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 15:19 JST
|
|
|
Baguio Green's 2023 Adjusted Net Profit increased by 36.7%
Mar 29, 2024 14:15 HKT/SGT
|
|
|
尚晋国际公布2023年全年业绩
Mar 29, 2024 13:48 HKT/SGT
|
|
|
尚晉國際公布2023年全年業績
Mar 29, 2024 13:38 HKT/SGT
|
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 29, 2024 14:32 JST
|
|
|
Forward Fashion Announced 2023 Annual Results
Mar 29, 2024 13:29 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|